Exclusive Summary

• Adefovir dipivoxil tablets are off-patent, leading to a mature generics market with high global demand for cost-effective treatment, especially in price-sensitive regions.
• Chronic Hepatitis B is a global health burden, and despite newer drugs, Adefovir remains a crucial second-line or alternative treatment option worldwide, particularly for underserved populations and emerging markets, due to its cost-effectiveness.
• The product boasts international quality standards and comprehensive registration dossiers, enabling rapid market entry and meeting the swift launch requirements of distribution partners.
• Compared to the originator and newer nucleos(t)ide analogs, Adefovir dipivoxil offers a significant cost advantage, enhancing patient accessibility and reducing healthcare expenditures.
• As a BD intermediary, we connect overseas pharmaceutical companies with high-quality, competitive Chinese generic manufacturers, facilitating efficient global market distribution.